Physician profile
Suvrat Bhargave
NPI 1720070501
$1,072,583.46
in general payments reported to CMS, 2019-2025
27 companies · $183K in 2025
The $183K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $23K · 2021: $118K · 2022: $213K · 2023: $255K · 2024: $178K · 2025: $183K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $419K · Travel and Lodging: $78K · Honoraria: $50K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Consulting Fee: $27K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $418,575.00 |
| Travel and Lodging | $77,929.39 |
| Honoraria | $50,150.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,244.00 |
| Consulting Fee | $26,750.00 |
| Food and Beverage | $15,743.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561,506.67 | 2021-2025 | Vraylar |
| Corium, LLC | $229,590.49 | 2021-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $76,610.55 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Axsome Therapeutics, INC. | $71,394.09 | 2024-2025 | Auvelity |
| Allergan, INC. | $48,876.04 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $39,314.61 | 2019-2025 | Qelbree, Qelbree |
| Noven Pharmaceuticals, INC. | $26,855.57 | 2023-2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $10,063.48 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $4,969.43 | 2019-2021 | |
| Noven Therapeutics, LLC | $1,000.03 | 2023-2025 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $412.48 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Otsuka America Pharmaceutical, INC. | $372.72 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $298.62 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $260.76 | 2022-2025 | Aristada, Lybalvi |
| Alfasigma USA, INC. | $151.91 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $140.77 | 2019-2025 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.46 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $136.11 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $129.40 | 2019-2023 | Trintellix |
| Shire North American Group INC | $72.80 | 2019 | |
| Collegium Pharmaceutical, INC. | $59.52 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $58.48 | 2019 | |
| Idorsia Pharmaceuticals US INC | $55.86 | 2022-2023 | Quviviq |
| Lundbeck LLC | $43.67 | 2019-2024 | Rexulti |
| Bausch Health US, LLC | $37.44 | 2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $19.65 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $15.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suvrat Bhargave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.